down arrow

Minerva Surgical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US60343F2056
USD
0.00
0.00 (0.00%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

13

Shareholding (Dec 2023)

FII

1.06%

Held by 4 FIIs

DII

75.73%

Held by 1 DIIs

Promoter

22.66%

How big is Minerva Surgical, Inc.?

22-Jun-2025

As of Jun 18, Minerva Surgical, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap, with net sales of 51.68 million and a net profit loss of 33.45 million over the latest four quarters. As of Dec 22, the company's shareholder's funds were 17.18 million, and total assets were 68.90 million.

Market Cap: As of Jun 18, Minerva Surgical, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Minerva Surgical, Inc. reported net sales of 51.68 million. However, the company experienced a net profit loss of 33.45 million during the same period.<BR><BR>Balance Sheet Snapshot: As of Dec 22, the company's shareholder's funds amounted to 17.18 million, while total assets were reported at 68.90 million.

Read More

Is Minerva Surgical, Inc. overvalued or undervalued?

20-Sep-2025

As of May 11, 2022, Minerva Surgical, Inc. is rated as risky due to its overvaluation and poor financial metrics, including a P/E ratio of 0.00 and a one-year return of -99.17%, significantly underperforming compared to its peers and the S&P 500.

As of 11 May 2022, the valuation grade for Minerva Surgical, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0.00, an EV to EBIT of -0.85, and an EV to EBITDA of -1.14, which suggest a lack of profitability and operational efficiency. <BR><BR>In comparison to its peers, Silk Road Medical, Inc. has a P/E ratio of -19.76 and an EV to EBITDA of -18.12, while Cytek Biosciences, Inc. shows a P/E of -33.33 and an EV to EBITDA of -15.41, both indicating that Minerva Surgical is underperforming relative to its industry. Additionally, the company's one-year return of -99.17% starkly contrasts with the S&P 500's return of 17.14%, reinforcing the notion that Minerva Surgical is struggling significantly in the market.

Read More

Is Minerva Surgical, Inc. technically bullish or bearish?

20-Sep-2025

As of June 13, 2025, Minerva Surgical, Inc. shows a neutral technical trend with mixed indicators, including a mildly bullish MACD and bearish KST, while significantly underperforming the S&P 500 with a return of -99.17% compared to its 17.14%.

As of 13 June 2025, the technical trend for Minerva Surgical, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish monthly reading but none on the weekly. Moving averages indicate a mildly bearish daily trend. Additionally, the KST is bearish on the weekly and neutral on the monthly, and Dow Theory shows no trend in both time frames. <BR><BR>In terms of performance, the company has significantly underperformed the S&P 500 over the past year, with a return of -99.17% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.43

stock-summary
Return on Equity

-189.83%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Sep 2023)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
900.0%
0%
900.0%
1 Year
900.0%
0%
900.0%
2 Years
-99.95%
0%
-99.95%
3 Years
-99.46%
0%
-99.46%
4 Years
-100.0%
0%
-100.0%
5 Years
0%
0%
0.0%

Minerva Surgical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Minerva Surgical, Inc. technically bullish or bearish?

As of 13 June 2025, the technical trend for Minerva Surgical, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish monthly reading but none on the weekly. Moving averages indicate a mildly bearish daily trend. Additionally, the KST is bearish on the weekly and neutral on the monthly, and Dow Theory shows no trend in both time frames. In terms of performance, the company has significantly underperformed the S&P 500 over the past year, with a return of -99.17% compared to the S&P 500's 17.14%....

Read More

Is Minerva Surgical, Inc. overvalued or undervalued?

As of 11 May 2022, the valuation grade for Minerva Surgical, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0.00, an EV to EBIT of -0.85, and an EV to EBITDA of -1.14, which suggest a lack of profitability and operational efficiency. In comparison to its peers, Silk Road Medical, Inc. has a P/E ratio of -19.76 and an EV to EBITDA of -18.12, while Cytek Biosciences, Inc. shows a P/E of -33.33 and an EV to EBITDA of -15.41, both indicating that Minerva Surgical is underperforming relative to its industry. Additionally, the company's one-year return of -99.17% starkly contrasts with the S&P 500's return of 17.14%, reinforcing the notion that Minerva Surgical is struggling significantly in the market....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
24.60%
EBIT Growth (5y)
-133.07%
EBIT to Interest (avg)
-9.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.43
Sales to Capital Employed (avg)
2.33
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
25.65%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.85
EV to EBITDA
-1.14
EV to Capital Employed
0.59
EV to Sales
0.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-69.62%
ROE (Latest)
-189.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 8 Schemes (0.55%)

Foreign Institutions

Held by 4 Foreign Institutions (1.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is -4.76% vs 0.80% in Sep 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 36.28% vs -253.12% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.00",
          "val2": "12.60",
          "chgp": "-4.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.70",
          "val2": "-7.70",
          "chgp": "38.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.90",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-11.30",
          "chgp": "36.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-509.50%",
          "val2": "-834.80%",
          "chgp": "32.53%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -3.45% vs 37.83% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -58.60% vs -17.49% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "50.30",
          "val2": "52.10",
          "chgp": "-3.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.60",
          "val2": "-18.10",
          "chgp": "-58.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "11.70",
          "chgp": "-72.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "9.10",
          "val2": "19.60",
          "chgp": "-53.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.10",
          "val2": "-21.50",
          "chgp": "-58.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-795.20%",
          "val2": "-551.20%",
          "chgp": "-24.40%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
12.00
12.60
-4.76%
Operating Profit (PBDIT) excl Other Income
-4.70
-7.70
38.96%
Interest
1.20
0.90
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.20
-11.30
36.28%
Operating Profit Margin (Excl OI)
-509.50%
-834.80%
32.53%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2023 is -4.76% vs 0.80% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 36.28% vs -253.12% in Sep 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
50.30
52.10
-3.45%
Operating Profit (PBDIT) excl Other Income
-28.60
-18.10
-58.01%
Interest
3.20
11.70
-72.65%
Exceptional Items
9.10
19.60
-53.57%
Consolidate Net Profit
-34.10
-21.50
-58.60%
Operating Profit Margin (Excl OI)
-795.20%
-551.20%
-24.40%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -3.45% vs 37.83% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -58.60% vs -17.49% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Minerva Surgical, Inc. stock-summary
stock-summary
Minerva Surgical, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."